Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period.
Ramy H ElshabouryMiranda M MonkLisa M BebellMonique R BidellMeagan L AdamsickRonak G GandhiMolly L ParasElizabeth L HohmannAlyssa R LetourneauPublished in: Therapeutic advances in infectious disease (2021)
In this real-world experience, outcomes after 5 days of RDV therapy were comparable to those of clinical trials. Disease severity, age, and dexamethasone use influenced clinical outcomes. Time to RDV initiation appeared to affect recovery and 28-day mortality, a finding that should be explored further. Mortality rate decreased over the analysis period, which could be related to dexamethasone use and improved management of COVID-19.